CaCO3-Encapuslated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma

Transcatheter arterial embolization (TAE) is an extensively applied treatment method for hepatocellular carcinoma (HCC). However, the worsened tumor microenvironment (TME, e.g., reduced pH post-TAE) may result in unsatisfactory therapeutic outcome. Herein, a new kind of embolic agent, calcium carbonate encapsulated alginate microspheres (CaCO3-ALG MSs) are synthesized. Such CaCO3-ALG MSs are able to neutralize the tumor pH owing to the reaction of CaCO3 with protons, which would not affect the overall morphology of microspheres after decomposition of CaCO3. TAE treatment with CaCO3-ALG MSs is then conducted in an orthotopic rat liver cancer model. F-18-Fluorodeoxyglucose micropositron emission tomography/computed tomography imaging is conducted post-TAE and discovered that intra-arterial injection of CaCO3-ALG MSs shows obvious enhanced therapeutic outcome compared to the same treatment with bare ALG MSs or the clinically used lipiodol. Further studies including analysis of immune cells in tumors, cytokine assays, and bioinformatics analysis all verify the reverse of immunosuppressive TME toward a more immunosupportive one after TAE with CaCO3-ALG MSs. The research not only presents a new CaCO3-containing embolic agent for enhanced TAE treatment of HCC but also highlights a clinically meaningful approach to improve cancer treatment via tumor pH neutralization.

Automated summary

Researchers synthesized a new embolic agent, CaCO3-ALG MSs, which can neutralize tumor pH and enhance therapeutic outcome. Animal experiments and imaging results showed that TAE treatment with CaCO3-ALG MSs had significant improvement compared to other methods, highlighting the potential of pH neutralization in improving cancer treatment.